The company develops neuroprotective molecular spacers with the aim of preventing neurodegeneration in the brain. They utilize peptides and gene therapy methods for detecting genetic variations, and specialize in a new category of medications for addressing neurological disorders, offering a pharmacological approach for patients with untreated human neurological conditions.
FundaMental Pharma
Headquarters
Germany